AIM: To determine the safety profile of new hepatitis C virus（HCV） treatments in liver transplant（LT） recipients with recurrent HCV infection.METHODS: Forty-two patients were identified with recurrent HCV infection that underwent LT at least 12 mo prior to initiating treatment with a Sofosbuvir-based regimen during December 2013-June 2014. Cases were patients who experienced hepatic decompensation and/or serious adverse events（SAE） during or within one month of completing treatment. Controls had... 

【文章頁數(shù)】：11 頁

【參考文獻】：
期刊論文
[1]Management of hepatitis C infection before and after liver transplantation[J]. Stefano Fagiuoli,Roberto Ravasio,Maria Grazia Lucà,Anna Baldan,Silvia Pecere,Alessandro Vitale,Luisa Pasulo.  World Journal of Gastroenterology. 2015(15)



本文編號：3671167